Will I regain weight after stopping tirzepatide?

Weight regain is common, but the amount varies and it is not immediate or inevitable. In SURMOUNT-4, participants switched to placebo gained an average of 14.0% of their week-36 weight over the next year. They still averaged 9.9% below their original baseline, and individual outcomes were spread around those group averages.

How soon does appetite return after stopping tirzepatide?

Appetite may become more noticeable over days to several weeks as tirzepatide exposure falls. The drug's half-life is about five days, and most of it clears over roughly 25 to 30 days. Studies have not identified one reliable day when hunger returns, so dose, treatment duration and individual response all matter.

Does tirzepatide cause withdrawal symptoms?

Tirzepatide is not known to cause a classic pharmacological withdrawal syndrome. People may notice more hunger, less prolonged fullness or changing blood sugar as its treatment effects fade. Those changes reflect the return of physiology the medication had been modifying, rather than addiction or a characteristic cluster of acute withdrawal symptoms.

Do you need to taper off tirzepatide?

Not necessarily. There is no established taper-to-zero schedule shown to prevent weight regain or an acute withdrawal syndrome. A prescriber may reduce the dose gradually to observe appetite, weight, glucose or tolerability, but may recommend a different plan depending on why treatment is ending and which health conditions are being managed.

Can tirzepatide be used at a lower maintenance dose?

A lower dose can be a maintenance option for some adults. In the 2026 SURMOUNT-MAINTAIN trial, reducing from a maximum tolerated 10 or 15 mg dose to 5 mg preserved more average weight reduction than switching to placebo, though full-dose continuation preserved more. The right maintenance dose remains an individualized prescribing decision.

What happens to blood sugar after stopping tirzepatide?

Blood sugar may rise as tirzepatide's glucose-lowering effect fades, particularly in someone with type 2 diabetes. SURMOUNT-4 excluded people with diabetes, so its weight-regain figures do not answer that clinical question directly. A stopping plan can include glucose or A1c follow-up and coordinated changes to other diabetes medications when appropriate.

What Happens When You Stop Taking Tirzepatide?

What happens when you stop taking tirzepatide is usually a gradual return of appetite and less prolonged fullness as the medication clears, followed by some degree of weight regain for many people. Tirzepatide is not known to cause a classic pharmacological withdrawal syndrome. The change is the loss of an active treatment effect, not addiction. The drug takes roughly 25 to 30 days to wash out, while weight changes unfold over months rather than overnight.

What happens when you stop taking tirzepatide: the timeline

Tirzepatide has an elimination half-life of about five days, according to a population pharmacokinetic analysis that pooled 19 studies (Schneck and Urva, CPT: Pharmacometrics & Systems Pharmacology 2024). After one half-life, about half of the drug remains; after five, roughly 3% remains. That is why tirzepatide can remain in the body for about a month after the last injection.

Time after the last dose	What may be changing	What the evidence can tell us
First week	Drug exposure is falling, but a substantial amount remains	There is no precise day when appetite changes for everyone
Weeks 2–4	Medication-driven fullness, appetite control and delayed gastric emptying may fade	Washout is gradual; symptoms and timing vary by dose and person
Months 1–6	A weight trend may become visible	In SURMOUNT-4, the withdrawal group had gained 10.0% from its randomization weight by week 28
By one year	Regain was common, but outcomes varied	The withdrawal group averaged a 14.0% increase from its randomization weight

Tirzepatide can reduce hunger and food intake while it is active. A six-week randomized phase 1 trial found lower appetite, cravings and perceived hunger with tirzepatide than with placebo (Martin et al., Nature Medicine 2025). A separate human study found that tirzepatide delayed gastric emptying after a single dose, with the effect diminishing after repeated doses (Urva et al., Diabetes, Obesity and Metabolism 2020). Neither study mapped the exact day these effects return after stopping, so a personal timeline cannot be predicted from the half-life alone.

What SURMOUNT-4 found about weight regain

SURMOUNT-4 gives the clearest tirzepatide-specific answer. Everyone first received tirzepatide for 36 weeks, reaching a maximum tolerated dose of 10 or 15 mg. The 670 people who entered the randomized phase had lost an average of 20.9% of their starting body weight. They then either continued tirzepatide or switched to placebo for another 52 weeks, while both groups continued lifestyle counseling.

From week 36 to week 88, the group switched to placebo gained an average of 14.0% of its week-36 weight. The group continuing tirzepatide lost another 5.5%. At week 88, 89.5% of those continuing treatment had kept at least 80% of their initial loss, compared with 16.6% of those switched to placebo (Aronne et al., JAMA 2024). The 14.0% figure is a percentage of body weight at randomization, not 14% of the pounds previously lost.

Stopping did not mean everyone returned to their original weight. From the start of the trial through week 88, the withdrawal group still averaged 9.9% below baseline. That spread matters: trial averages describe a group, not an individual forecast. Our guide to tirzepatide weight-loss results puts the broader treatment curve in context.

A 2026 post hoc analysis looked more closely at 308 withdrawal participants who had initially lost at least 10%. Within one year, 82.5% had regained at least one-quarter of the weight they had lost. Greater regain generally accompanied greater reversal of improvements in waist circumference, blood pressure, cholesterol, blood sugar and fasting insulin (Horn et al., JAMA Internal Medicine 2026).

Tirzepatide withdrawal is not a withdrawal syndrome

The phrase "tirzepatide withdrawal" is useful for describing treatment withdrawal in a trial, but it can sound like the drug causes dependence. Current clinical evidence does not show a characteristic acute withdrawal syndrome. SURMOUNT-4 tracked adverse events after participants switched to placebo and found the clinically important pattern was gradual weight and cardiometabolic change.

What can feel abrupt is the contrast. Hunger, interest in food or the ability to eat larger portions may become more noticeable as active drug exposure declines. Nausea, constipation or excessive fullness may also ease. That does not mean the body has failed. It means the signals that tirzepatide had been modifying are no longer being modified to the same degree.

Maintenance dosing, dose reduction and tapering

Stopping completely is not the only maintenance option a prescriber may consider. SURMOUNT-MAINTAIN, published in The Lancet in 2026, enrolled adults who first received a maximum tolerated 10 or 15 mg dose for 60 weeks. Then 378 participants were assigned to continue that dose, reduce to 5 mg or switch to placebo for 52 weeks. From the original baseline to week 112, estimated average weight changes were -21.9%, -16.6% and -9.9%, respectively (Horn et al., The Lancet 2026).

That trial supports dose reduction as a possible maintenance strategy for some adults; it does not establish one universal maintenance dose. It also did not test a taper all the way to zero. A gradual reduction may give a clinician time to watch appetite, weight, glucose and tolerability, but tapering has not been shown necessary to prevent an acute withdrawal syndrome or sufficient to prevent regain. The tirzepatide dosage schedule explains why dose changes are individualized.

Switching to semaglutide is a medication change, not the same as stopping treatment. Its discontinuation evidence should be considered separately; what happens after stopping semaglutide covers that question without treating the two drugs as interchangeable.

Lifestyle support matters, without moralizing regain

A stopping plan can build around routines that remain when medication-driven appetite control fades: repeatable meals, adequate protein and fiber, resistance and aerobic activity, sleep, and scheduled follow-up. These are scaffolding, not proof of willpower. SURMOUNT-4 participants received diet and activity counseling throughout, yet average regain still occurred after the medication was withdrawn.

Follow-up can track more than the scale. Waist circumference, blood pressure and laboratory measures may matter, especially for someone with type 2 diabetes or another weight-related condition. Restarting after a long gap, changing to another drug or using a lower maintenance dose are prescribing decisions rather than do-it-yourself adjustments.

Make the stopping decision with the prescriber

Tirzepatide manages ongoing biology; it does not turn weight regulation into a moral test. Whether to continue at a maintenance dose, reduce the dose or stop is a decision for the patient and prescriber, based on response, risks and goals. Cost, side effects, pregnancy plans, surgery and changing health needs can all alter that calculation.

At Promise, a licensed provider reviews every request, and not everyone qualifies. A thoughtful plan sets the next check-in and the measures that would trigger a new conversation, rather than treating the last injection as the end of care.